These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23113663)

  • 21. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
    Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
    HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
    HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
    Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
    Li M; Chan WW; Zucker SD
    J Am Heart Assoc; 2020 Oct; 9(19):e016310. PubMed ID: 32930032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of Gilbert's syndrome: role of reduced caloric intake test.
    Owens D; Sherlock S
    Br Med J; 1973 Sep; 3(5880):559-63. PubMed ID: 4726927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atazanavir: its role in HIV treatment.
    Wood R
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
    Rodríguez-Nóvoa S; Morello J; González M; Vispo E; Barreiro P; González-Pardo G; Jiménez-Nácher I; Gonzalez-Lahoz J; Soriano V
    AIDS; 2008 Nov; 22(18):2535-7. PubMed ID: 19005277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atazanavir: a review of its use in the management of HIV-1 infection.
    Croom KF; Dhillon S; Keam SJ
    Drugs; 2009 May; 69(8):1107-40. PubMed ID: 19496633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
    Honda M; Ishisaka M; Ishizuka N; Kimura S; Oka S;
    Intern Med; 2011; 50(7):699-705. PubMed ID: 21467701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
    Ribaudo HJ; Daar ES; Tierney C; Morse GD; Mollan K; Sax PE; Fischl MA; Collier AC; Haas DW;
    J Infect Dis; 2013 Feb; 207(3):420-5. PubMed ID: 23148286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
    Mandelbrot L; Mazy F; Floch-Tudal C; Meier F; Azria E; Crenn-Hebert C; Treluyer JM; Herinomenzanahary E; Ferreira C; Peytavin G
    Eur J Obstet Gynecol Reprod Biol; 2011 Jul; 157(1):18-21. PubMed ID: 21492993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O; Josephson F; Sönnerborg A
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection.
    Nishijima T; Shimbo T; Komatsu H; Hamada Y; Gatanaga H; Kikuchi Y; Oka S
    J Antimicrob Chemother; 2014 May; 69(5):1385-9. PubMed ID: 24379301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
    Carey D; Amin J; Boyd M; Petoumenos K; Emery S
    J Antimicrob Chemother; 2010 Sep; 65(9):1878-88. PubMed ID: 20554568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
    Guaraldi G; Cocchi S; Motta A; Ciaffi S; Codeluppi M; Bonora S; Di Benedetto F; Masetti M; Floridia M; Baroncelli S; Pinetti D; D'Avolio A; Bertolini A; Esposito R
    J Antimicrob Chemother; 2008 Dec; 62(6):1356-64. PubMed ID: 18776190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    Rekić D; Clewe O; Röshammar D; Flamholc L; Sönnerborg A; Ormaasen V; Gisslén M; Abelö A; Ashton M
    AAPS J; 2011 Dec; 13(4):598-605. PubMed ID: 21913053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
    Park WB; Choe PG; Song KH; Jeon JH; Park SW; Kim HB; Kim NJ; Oh MD; Choe KW
    Clin Infect Dis; 2010 Jul; 51(1):101-6. PubMed ID: 20504240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.